与临床药理学家和临床医生合作推进儿科制剂高效开发:conect4children 专家组白皮书
该白皮书由 conect4children 专家组发布,建议采用儿科质量目标产品概况( paediatric Quality Target Product Profile)作为高效工具,促进新化学实体或专利过期药物再定位/再制剂过程中以儿童为中心的制剂设计早期规划与决策。文中提出并描述了儿科制剂的关键属性,倡导制剂专家与临床同事(包括医疗保健专业人员)加强合作,并建议将可接受性测试作为儿科临床试验的次要终点,以确保上市后依从性不因可接受性不足而受损。
要点
- 推荐使用儿科质量目标产品概况作为早期规划和决策工具。
- 提出并描述儿科制剂的关键属性。
- 倡导制剂专家与临床医生加强合作。
核心结论
- 儿科质量目标产品概况可作为有价值的协作工具,用于规划和决策以加速儿科产品开发。
研究设计与样本
- 本文为 conect4children 专家组白皮书(立场文件),基于专家意见提出建议。
主要发现
- 全球范围内儿科年龄适用制剂的可及性改善仍是优先事项,但儿科制剂上市仍落后于成人产品。
- 儿科制剂开发面临额外复杂性,主要与开发可接受的年龄适用儿科药物相关。
- 早期不了解适应症、相关年龄组和潜在给药方案仍是高效儿科制剂开发的主要障碍。
关键数值与推荐
- 推荐使用儿科质量目标产品概况作为高效工具,促进新化学实体或再定位/再制剂药物的早期规划和决策。
- 建议将可接受性测试作为儿科临床试验的次要终点。
临床怎么用
- 在儿科制剂开发早期采用儿科质量目标产品概况进行规划和决策。
- 制剂专家应与临床同事(包括医疗保健专业人员)加强合作。
- 在儿科临床试验中纳入可接受性测试作为次要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improved global access to novel age-appropriate formulations for paediatric subsets, either of new chemical entities or existing drugs, is a priority to ensure that medicines meet the needs of these patients. However, despite regulatory incentives, the introduction to the market of paediatric formulations still lags behind adult products. This is mainly caused by additional complexities associated with the development of acceptable age-appropriate paediatric medicines. This position paper recommends the use of a paediatric Quality Target Product Profile as an efficient tool to facilitate early planning and decision making across all teams involved in paediatric formulation development during the children-centric formulation design for new chemical entities, or to repurpose/reformulate off-patent drugs. Essential key attributes of a paediatric formulation are suggested and described. Moreover, greater collaboration between formulation experts and clinical colleagues, including healthcare professionals, is advocated to lead to safe and effective, age-appropriate medicinal products. Acceptability testing should be a secondary endpoint in paediatric clinical trials to ensure postmarketing adherence is not compromised by a lack of acceptability. Not knowing the indications and the related age groups and potential dosing regimens early enough is still a major hurdle for efficient paediatric formulation development; however, the proposed paediatric Quality Target Product Profile could be a valuable collaborative tool for planning and decision making to expedite paediatric product development, particularly for those with limited experience in developing a paediatric product.
引用
- Walsh J, Schaufelberger D, Iurian S, et al. Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper. Br J Clin Pharmacol. 2021. PMID: 34265091. doi:10.1111/bcp.14989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。